Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2
Screening HbA1c \<6.5 %
You may not be if
Previous documented diagnosis of diabetes mellitus
Self-reported change in body weight \>5% within 3 months before Screening
Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan
Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)
Clareo Health | Aleniglipron Phase 2 Body Composition Study
